Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3059-3065

  Pitart, C ^a   Marco, F ^a   Keating, T A ^b,c   Nichols, W W ^b   Vila, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ASTRAZENECA   (United Kingdom)

^c IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NALIDIXIC ACID; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

AZABICYCLO COMPOUNDS; CEFTAZIDIME; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 84955294377     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05136-14     Document Type: Article

References (19)

1. Endimiani A, Choudhary Y, Bonomo RA. 2009. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 53:3599-3601. http://dx.doi.org/10.1128/AAC.00641-09.
2. Aktaş Z, Kayacan C, Oncul O. 2012. In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing-Klebsiella pneumoniae. Int J Antimicrob Agents 39:86 - 89. http://dx.doi.org/10.1016/j.ijantimicag.2011.09.012.
3. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé- Wiens PRS, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β- lactamase inhibitor combination. Drugs 73:159-177. http://dx.doi.org/10.1007/s40265-013-0013-7.
4. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13:785-796. http://dx.doi.org/10.1016/S1473-3099(13)70190-7.
5. Livermore DM. 2001. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 47:247-250. http://dx.doi.org/10.1093/jac/47.3.247.
6. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J. 2004. Emergence of carbapenemresistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 39:55-60. http://dx.doi.org/10.1086/421495.
8. Tsakris A, Themeli-Digalaki K, Poulou A, Vrioni G, Voulgari E, Koumaki V, Agodi A, Pournaras S, Sofianou D. 2011. Comparative evaluation of combined-disk tests using different boronic acid compounds for detection of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae clinical isolates. J Clin Microbiol 49:2804-2809. http://dx.doi.org/10.1128/JCM.00666-11.
9. Navia MM, Ruiz J, Ribera A, de Anta MT, Vila J. 1999. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii. J Antimicrob Chemother 44:743-748. http://dx.doi.org/10.1093/jac/44.6.743.
10. Vila J, Ruiz J, Marco F, Barcelo A, Goñi P, Giralt E, Jimenez de Anta T. 1994. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother 38:2477-2479. http://dx.doi.org/10.1128/AAC.38.10.2477.
11. Vila J, Ruiz J, Goñi P, de Anta MT. 1996. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 40:491-493.
12. Vila J, Ruiz J, Goñi P, Marcos A, Jimenez de Anta T. 1995. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 39:1201-1203. http://dx.doi.org/10.1128/AAC.39.5.1201.
13. Fàbrega A, Merle du L, Le Bouguénec C, Jiménez de Anta MT, Vila J. 2009. Repression of invasion genes and decreased invasion in a high-level fluoroquinolone-resistant Salmonella Typhimurium mutant. PLoS One 4:e8029. http://dx.doi.org/10.1371/journal.pone.0008029.
14. Lagacé-Wiens PRS, Tailor F, Simner P, De Corby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. 2011. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother 55:2434-2437. http://dx.doi.org/10.1128/AAC.01722-10.
15. Flamm RK, Farrell DJ, Sader HS, Jones RN. 2014. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intraabdominal and urinary tract infections in U.S. medical centers (2012). J Antimicrob Chemother 69:1589-1598. http://dx.doi.org/10.1093/jac/dku025.
16. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2014. Ceftazidimeavibactam activity and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis 80:233-238. http://dx.doi.org/10.1016/j.diagmicrobio.2014.07.005.
17. Mushtaq S, Warner M, Livermore DM. 2010. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other nonfermenters. J Antimicrob Chemother 65:2376-2381. http://dx.doi.org/10.1093/jac/dkq306.
18. Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. 2014. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 58:1684-1692. http://dx.doi.org/10.1128/AAC.02429-13.
19. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390-394. http://dx.doi.org/10.1128/AAC.00756-10.